<DOC>
	<DOCNO>NCT01961388</DOCNO>
	<brief_summary>The study design non interventional collect data effectiveness acarbose metformin monotherapy , respectively , term change baseline post prandial blood glucose level end 16 week drug-naïve type 2 diabetic patient within carbohydrate consumption subgroup real-life treatment condition large sample type-2 diabetes patient India . The study begin study approval ethic committee.All drug naïve patient decision administer acarbose metformin monotherapy type 2 diabetes management make include study take informed consent.Patients observe 16 week ( 2 week ) .The study involve general examination patient , collection data like history disease , concomitant medication , drug dose , 24 hr dietary recall etc . The study plan enroll 12250 subject multiple study center spread across India . The study data analyze appropriate statistical method .</brief_summary>
	<brief_title>Study Assess Dietary Carbohydrate Content Indian Diabetics With Special Therapeutic View Effectiveness Acarbose Metformin Monotherapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Acarbose</mesh_term>
	<criteria>Drugnaïve ( i.e. , patient never treat antidiabetic drug screen ) patient decision administer monotherapy either acarbose metformin type2 diabetes management make attend physician basis best clinical practice medical patient need , consent participate study include Patients receive antidiabetic medication time enrollment study exclude . However , observation period , patient may receive additional antidiabetic medication decision investigator . Exclusion criterion read conjunction local product information . All contraindication accord local marketing authorization consider</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Type 2 Diabetes</keyword>
</DOC>